n*n
2 楼
富马酸二甲酯，
这么简单的药物，当初怎么发现的？
专利没有问题吗
这么简单的药物，当初怎么发现的？
专利没有问题吗
F*n
3 楼
这个月的 statement还没出吧
【在 p******n 的大作中提到】
: 我消费了总得有八百grocery这个月，才17的reward啊
【在 p******n 的大作中提到】
: 我消费了总得有八百grocery这个月，才17的reward啊
p*u
4 楼
Dimethyl fumarate has won FDA approval to treat relapsing-remitting forms of
multiple sclerosis and will be sold under the name Tecfidera, the agency
said Wednesday.
Manufactured by Biogen Idec, the drug is also known as BG-12. It becomes the
third oral disease-modifying medication available to treat MS. Others
include fingolimod (Gilenya) and teriflunomide (Aubagio).
Dimethyl fumarate has a novel mechanism of action relative to existing MS
drugs. It is believed to activate the nuclear factor-like 2 transcriptional
pathway, thereby reducing oxidative stress that contributes strongly to
demyelination.
The drug has also been used for many years in Europe and elsewhere to treat
psoriasis, and has also been used as a fungicide and desiccant in furniture
manufacture.
Two placebo-controlled phase III trials served as the basis for approval,
the agency said. Called DEFINE and CONFIRM, they enrolled a total of some 2,
700 patients. In addition to comparing the drug with placebo, CONFIRM
included a third arm with open-label glatiramer acetate (Copaxone), a
standard injectable MS drug.
Both trials demonstrated that dimethyl fumarate was superior to placebo in
preventing relapses and delaying disability progression. It also appeared to
be somewhat more effective than glatiramer acetate in CONFIRM.
The most common adverse effects were gastrointestinal complaints and
flushing. The FDA also noted that the drug carries a risk of lymphocytopenia
, although infections did not appear to be increased as a result in the
phase III studies.
"No drug provides a cure for multiple sclerosis so it is important to have a
variety of treatment options available for patients," said Russell Katz, MD
, director of the Division of Neurology Products in the FDA's Center for
Drug Evaluation and Research, in a statement announcing the approval.
A Biogen competitor, Teva Pharmaceuticals, had petitioned the FDA to hold an
advisory committee meeting on the drug before approving it, citing the
hematologic effects and other risks, but the agency declined to do so.
http://www.medpagetoday.com/Neurology/MultipleSclerosis/38122?i
multiple sclerosis and will be sold under the name Tecfidera, the agency
said Wednesday.
Manufactured by Biogen Idec, the drug is also known as BG-12. It becomes the
third oral disease-modifying medication available to treat MS. Others
include fingolimod (Gilenya) and teriflunomide (Aubagio).
Dimethyl fumarate has a novel mechanism of action relative to existing MS
drugs. It is believed to activate the nuclear factor-like 2 transcriptional
pathway, thereby reducing oxidative stress that contributes strongly to
demyelination.
The drug has also been used for many years in Europe and elsewhere to treat
psoriasis, and has also been used as a fungicide and desiccant in furniture
manufacture.
Two placebo-controlled phase III trials served as the basis for approval,
the agency said. Called DEFINE and CONFIRM, they enrolled a total of some 2,
700 patients. In addition to comparing the drug with placebo, CONFIRM
included a third arm with open-label glatiramer acetate (Copaxone), a
standard injectable MS drug.
Both trials demonstrated that dimethyl fumarate was superior to placebo in
preventing relapses and delaying disability progression. It also appeared to
be somewhat more effective than glatiramer acetate in CONFIRM.
The most common adverse effects were gastrointestinal complaints and
flushing. The FDA also noted that the drug carries a risk of lymphocytopenia
, although infections did not appear to be increased as a result in the
phase III studies.
"No drug provides a cure for multiple sclerosis so it is important to have a
variety of treatment options available for patients," said Russell Katz, MD
, director of the Division of Neurology Products in the FDA's Center for
Drug Evaluation and Research, in a statement announcing the approval.
A Biogen competitor, Teva Pharmaceuticals, had petitioned the FDA to hold an
advisory committee meeting on the drug before approving it, citing the
hematologic effects and other risks, but the agency declined to do so.
http://www.medpagetoday.com/Neurology/MultipleSclerosis/38122?i
b*t
5 楼
等到下个statement也很正常
c*t
6 楼
在due date和statement之间的先算1%，剩下4%在下一个月出。
【在 p******n 的大作中提到】
: 我消费了总得有八百grocery这个月，才17的reward啊
【在 p******n 的大作中提到】
: 我消费了总得有八百grocery这个月，才17的reward啊
s*g
7 楼
你确定买的都是grocery店？
c*u
8 楼
walmart到底算不算，有个确切的答案吗
相关阅读
看看老外怎么讨论生物研究生和博士后的现状和出路问个问题：关于研究生被逼而亡的事美国科学博士无奈 失业后想找工作真的好难【ZZ】 (转载)发文章的烦恼，请求大家指点FAQ should learn from this收到OFFER LETTERl (转载)epigenetics faculty opportunity中国很多大学都不逊色于美国顶尖大学，除了学术水平。药厂逐渐抛弃化学专业，转向生物？请问新泽西癌症研究所的Hu wenwei这个导师怎么样？和flox老鼠杂交得cre老鼠用纯合子还是杂合的？自己掏腰包开会的多么？生物的兴趣以及苦逼PI问题你的文章发表需要帮助吗?问个加Flag的问题求推荐做Chip-Seq的tag一个朋友转业成功解决生物科研苦逼的制度性思考生命科学是所有学科的核心和前沿学科-施一公Sci Transl Med 含氧脂质体给停止呼吸的兔子供氧